The Patent Finder
PT

Paragon Therapeutics, Inc.

First filing 2024
OverviewNotableFeesChangesFamiliesPatent listSources & methods

14 patents currently held

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in May 2044. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
May 2044
Next term end
8
Patent families

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
notable patents all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

  • 2 of the patents on this record were granted since Aug 21, 2026

What they patent

The largest of its 8 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 12,304,956Dosing Regimen for Treating Inflammatory Bowel Disease
In force
 · High confidence
In forceHigh confidence
US 12,404,334Methods of Treating Gastrointestinal Inflammatory Disease
In force
 · High confidence
In forceHigh confidence
US 12,703,749Method of Treating Inflammatory Bowel Disease
In force
 · High confidence
In forceHigh confidence
US 12,760,108Injectable Formulations for Treatment of Inflammatory Bowel Disease
In force
 · Medium confidence
In forceMedium confidence
US 12,466,890TL1A Binding Proteins and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 12,509,523TL1A Binding Proteins and Methods of Use
In force
 · Medium confidence
In forceMedium confidence
US 12,606,627ALPHA4BETA7 Integrin Binding Proteins and Methods of Use
In force
 · Medium confidence
In forceMedium confidence
US 12,522,655IL-23 Antibody Compositions and Methods of Use
In force
 · Medium confidence
In forceMedium confidence
US 12,655,208IL-23 Binding Protein Compositions and Methods of Use
In force
 · Medium confidence
In forceMedium confidence
US 12,459,994Albumin Binding Proteins and Methods of Use
In force
 · Medium confidence
In forceMedium confidence
10 of 14 patents shown.
Pro members see all 14.
Pro members: see all 14 patents
Also on record, not counted in the 14: 18 applications pending · 1 application abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
10 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited